Related Experiment Videos
Abstract:
Swiss mice received chronic treatment with the schistosomacide, niridazole, at 3 dose levels. Tumors were found in several organs, including stomach, lung, manary gland, ovary and bladder. Niridazole is, without doubt, carcinogenic to mice.
Insights
Niridazole, a schistosomacide drug, was found to be carcinogenic in mice. Chronic treatment led to tumors in multiple organs, confirming its cancer-causing potential.
Area of Science:
- Toxicology
- Oncology
- Pharmacology
Background:
- Schistosomiasis is a significant parasitic disease.
- Antiparasitic drugs require thorough safety evaluations.
- Niridazole is a known schistosomacide used in treating schistosomiasis.
Purpose of the Study:
- To investigate the carcinogenic potential of niridazole.
- To evaluate the long-term effects of niridazole treatment in a mammalian model.
Main Methods:
- Swiss mice were administered chronic treatment with niridazole.
- Three distinct dose levels were utilized.
- Tumor development was monitored across various organs.
Main Results:
- Tumors were observed in multiple organs, including the stomach, lungs, mammary gland, ovaries, and bladder.
- A clear correlation between niridazole treatment and tumor incidence was established.
Conclusions:
- Niridazole demonstrates clear carcinogenic activity in mice.
- The findings raise concerns regarding the long-term safety of niridazole and necessitate further investigation into its mechanisms of carcinogenesis.